|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McIntyre A and Ganti AK: Lung cancer-a
global perspective. J Surg Oncol. 115:550–554. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Glatzer M, Elicin O, Ramella S, Nestle U
and Putora PM: Radio(chemo)therapy in locally advanced nonsmall
cell lung cancer. Eur Respir Rev. 25:65–70. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patel MI, Cheng I and Gomez SL: US lung
cancer trends by histologic type. Cancer. 121:1150–1152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang L, Li M, Wu N and Chen Y: Time
trends in epidemiologic characteristics and imaging features of
lung adenocarcinoma: A population study of 21,113 cases in China.
PLoS One. 10:e01367272015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ,
Dobelbower M, et al: Non-small cell lung cancer, version 5.2017,
NCCN clinical practice guidelines in oncology. J Natl Compr Canc
Netw. 15:504–535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jung CY and Antonia SJ: Tumor immunology
and immune checkpoint inhibitors in non-small cell lung cancer.
Tuberc Respir Dis (Seoul). 81:29–41. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rabbani M, Kanevsky J, Kafi K, Chandelier
F and Giles FJ: Role of artificial intelligence in the care of
patients with nonsmall cell lung cancer. Eur J Clin Invest.
482018.doi: 10.1111/eci.12901.
|
|
9
|
Walter AO, Sjin RT, Haringsma HJ, Ohashi
K, Sun J, Lee K, Dubrovskiy A, Labenski M, Zhu Z, Wang Z, et al:
Discovery of a mutant-selective covalent inhibitor of EGFR that
overcomes T790M-mediated resistance in NSCLC. Cancer Discov.
3:1404–1415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Passiglia F, Listí A, Castiglia M, Perez
A, Rizzo S, Bazan V and Russo A: EGFR inhibition in NSCLC: New
findings.. and opened questions? Crit Rev Oncol Hematol.
112:126–135. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fu Q, Song X, Liu Z, Deng X, Luo R, Ge C,
Li R, Li Z, Zhao M, Chen Y, et al: miRomics and proteomics reveal a
miR-296-3p/PRKCA/FAK/Ras/c-Myc feedback loop modulated by
HDGF/DDX5/β-catenin complex in lung adenocarcinoma. Clin Cancer
Res. 23:6336–6350. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakamura H, Kambe H, Egawa T, Kimura Y,
Ito H, Hayashi E, Yamamoto H, Sato J and Kishimoto S: Partial
purification and characterization of human hepatoma-derived growth
factor. Clin Chim Acta. 183:273–284. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bao CH, Liu K, Wang XT, Ma W, Wang JB,
Wang C, Jia YB, Wang NN, Tan BX, Song QX and Cheng YF: Prognostic
role of hepatoma-derived growth factor in solid tumors of Eastern
Asia: A systematic review and meta-analysis. Asian Pac J Cancer
Prev. 16:1803–1811. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao J, Ma MZ, Ren H, Liu Z, Edelman MJ,
Pan H and Mao L: Anti-HDGF targets cancer and cancer stromal stem
cells resistant to chemotherapy. Clin Cancer Res. 19:3567–3576.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baier G: The PKC gene module: Molecular
biosystematics to resolve its T cell functions. Immunol Rev.
192:64–79. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo Y, Bao Y, Ma M, Zhang S, Zhang Y, Yuan
M, Liu B, Yang Y, Cui W, Ansong E, et al: Clinical significance of
the correlation between PLCE 1 and PRKCA in esophageal inflammation
and esophageal carcinoma. Oncotarget. 8:33285–33299.
2017.PubMed/NCBI
|
|
17
|
Paraboschi EM, Rimoldi V, Soldá G,
Tabaglio T, Dall'Osso C, Saba E, Vigliano M, Salviati A, Leone M,
Benedetti MD, et al: Functional variations modulating PRKCA
expression and alternative splicing predispose to multiple
sclerosis. Hum Mol Genet. 23:6746–6761. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rosenberg S, Simeonova I, Bielle F,
Verreault M, Bance B, Le Roux I, Daniau M, Nadaradjane A, Gleize V,
Paris S, et al: A recurrent point mutation in PRKCA is a hallmark
of chordoid gliomas. Nat Commun. 9:23712018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edge SB, Byrd DR, Compton CC, et al: AJCC
7th Edition Cancer Staging Manual. 2010. https://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx22–10.
2015
|
|
20
|
Liu Z, Li L, Yang Z, Luo W, Li X, Yang H,
Yao K, Wu B and Fang W: Increased expression of MMP9 is correlated
with poor prognosis of nasopharyngeal carcinoma. BMC Cancer.
10:2702010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tu L, Liu Z, He X, He Y, Yang H, Jiang Q,
Xie S, Xiao G, Li X, Yao K and Fang W: Over-expression of
eukaryotic translation initiation factor 4 gamma 1 correlates with
tumor progression and poor prognosis in nasopharyngeal carcinoma.
Mol Cancer. 9:782010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xu H, Jin X, Yuan Y, Deng P, Jiang L, Zeng
X, Li XS, Wang ZY and Chen QM: Prognostic value rom integrative
analysis of transcription factors c-Jun and Fra-1 in oral squamous
cell carcinoma: A multicenter cohort study. Sci Rep. 7:75222017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Philipsen S: Expression data for early
stage NSCLC. 2010. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE1918810–06.
2017
|
|
24
|
Cai S, Cai J, Jiang WG and Ye L: Kidins220
and tumour development: Insights into a complexity of cross-talk
among signalling pathways (Review). Int J Mol Med. 40:965–971.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bica-Pop C, Cojocneanu-Petric R, Magdo L,
Raduly L, Gulei D and Berindan-Neagoe I: Overview upon miR-21 in
lung cancer: Focus on NSCLC. Cell Mol Life Sci. 75:3539–3551. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jing P, Zhao N, Xie N, Ye M, Zhang Y,
Zhang Z, Li M, Lai X, Zhang J and Gu Z: miR-24-3p/FGFR3 Signaling
as a novel axis is involved in epithelial-mesenchymal transition
and regulates lung adenocarcinoma progression. J Immunol Res.
2018:28341092018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li W, Qiu T, Guo L, Ling Y, Gao Y, Ying J
and He J: Primary and acquired EGFR T790M-mutant NSCLC patients
identified by routine mutation testing show different
characteristics but may both respond to osimertinib treatment.
Cancer Lett. 423:9–15. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin L, Zhao J, Hu J, Zou G, Huang F, Han
J, He Y and Cao X: Current smoking has a detrimental effect on
survival for epidermal growth factor receptor (EGFR) and anaplastic
lymphoma kinase (ALK) negative advanced non-squamous Non-small cell
lung cancer (NSCLC) patients treated with pemetrexed continuation
maintenance. J Cancer. 9:2140–2146. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Su C, Cheng X, Li Y, Han Y, Song X, Yu D,
Cao X and Liu Z: MiR-21 improves invasion and migration of
drug-resistant lung adenocarcinoma cancer cell and transformation
of EMT through targeting HBP1. Cancer Med. 7:2485–2503. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nakamura H, Izumoto Y, Kambe H, Kuroda T,
Mori T, Kawamura K, Yamamoto H and Kishimoto T: Molecular cloning
of complementary DNA for a novel human hepatoma-derived growth
factor. Its homology with high mobility group-1 protein. J Biol
Chem. 269:25143–25149. 1994.PubMed/NCBI
|
|
31
|
Enomoto H, Nakamura H, Liu W and
Nishiguchi S: Hepatoma-derived growth factor: Its possible
involvement in the progression of hepatocellular carcinoma. Int J
Mol Sci. 16:14086–14097. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li M, Shen J, Wu X, Zhang B, Zhang R, Weng
H, Ding Q, Tan Z, Gao G, Mu J, et al: Downregulated expression of
hepatoma- derived growth factor (HDGF) reduces gallbladder cancer
cell proliferation and invasion. Med Oncol. 30:5872013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang L, Jiang Q, Hua S, Zhao M, Wu Q, Fu
Q, Fang W and Guo S: High nuclear expression of HDGF correlates
with disease progression and poor prognosis in human endometrial
carcinoma. Dis Markers. 2014:2987952014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu Y, Sun J, Yang G, Liu Z, Guo S, Zhao
R, Xu K, Wu X and Zhang Z: Downregulation of the expression of HDGF
attenuates malignant biological behaviors of hilar
cholangiocarcinoma cells. Mol Med Rep. 12:4713–4719. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim YD, Jeon JY, Woo HJ, Lee JC, Chung JH,
Song SY, Yoon SK and Baek SH: Interleukin-1beta induces MUC2 gene
expression and mucin secretion via activation of PKC-MEK/ERK, and
PI3K in human airway epithelial cells. J Korean Med Sci.
17:765–771. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lee HY, Crawley S, Hokari R, Kwon S and
Kim YS: Bile acid regulates MUC2 transcription in colon cancer
cells via positive EGFR/PKC/Ras/ERK/CREB,
PI3K/Akt/IkappaB/NF-kappaB and p38/MSK1/CREB pathways and negative
JNK/c-Jun/AP-1 pathway. Int J Oncol. 36:941–953. 2010.PubMed/NCBI
|
|
37
|
O'Brian C, Vogel VG, Singletary SE and
Ward NE: Elevated protein kinase C expression in human breast tumor
biopsies relative to normal breast tissue. Cancer Res.
49:3215–3217. 1989.PubMed/NCBI
|
|
38
|
Kopp R, Noelke B, Sauter G, Schildberg FW,
Paumgartner G and Pfeiffer A: Altered protein kinase C activity in
biopsies of human colonic adenomas and carcinomas. Cancer Res.
51:205–210. 1991.PubMed/NCBI
|
|
39
|
Wang C, Wang X, Liang H, Wang T, Yan X,
Cao M, Wang N, Zhang S, Zen K, Zhang C and Chen X: miR-203 inhibits
cell proliferation and migration of lung cancer cells by targeting
PKCα. PLoS One. 8:e739852013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lahn M, Sundell K and Köhler G: The role
of protein kinase C-alpha in hematologic malignancies. Acta
Haematol. 115:1–8. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lahn M, Su C, Li S, Chedid M, Hanna KR,
Graff JR, Sandusky GE, Ma D, Niyikiza C, Sundell KL, et al:
Expression levels of protein kinase C-alpha in non-small-cell lung
cancer. Clin Lung Cancer. 6:184–189. 2004. View Article : Google Scholar : PubMed/NCBI
|
